Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02204085 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT02204085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02204085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2014
Completion date
December 31, 2025
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, in relapse, recurrent adult acute myeloid leukemia